Could a chimeric condition be responsible for unexpected genetic syndromes? The role of the single nucleotide polymorphism-array analysis

To the Editor

The term “chimerism” refers to the presence of two or more genetically distinct cell lineages originating from different zygotes in the same individual and can be easily distinguished from mosaicism by the extent of genotypic differences along the genome. Chimeras generally come to medical attention when they contain both male and female cells (46,XX/46,XY karyotype), causing disorders of sex development, or a discrepancy between external genitalia and chromosomal sex (Malan, Vekemans, & Turleau, 2006). In phenotypically normal individuals, chimerism may come to light only if there is a reason to perform genetic testing, that is, blood typing discrepancy (Drexler et al., 2005) or paternity testing (Ramsay et al., 2009). All the other chimeric individuals would not be detectable by standard cytogenetic technology, suggesting that this phenomenon might be underdiagnosed. About the origin of chimera individuals, four principal mechanisms have been identified as follows: (a) Tetragametic chimera (Green, Barton, Jenks, Pearson, & Yates, 1994); (b) Androgenetic chimera (Kaiser-Rogers et al., 2006); (c) Fertilization of an ovum and a second polar body by two different spermatozoa and subsequent fusion of the two zygotes (Green et al., 1994); and (d) Parthenogenetic chimera (Giltay et al., 1998).

Herein, we present two patients characterized by a Silver–Russell- and Prader–Willi-like phenotypes in which, despite a genetically normal karyotype detected in blood, a genome-wide single nucleotide polymorphism (SNP) array analysis on DNA from skin biopsies highlighted a chimeric status.

We discuss SNP array as a technique able to identify chimerism also suggesting which one of the complex mechanisms underlying chimera formation could be responsible (Biesecker & Spinner, 2013). Subsequently, a custom next-generation sequence (NGS) panel was used for chimerism quantification (Aloisio et al., 2016).

Based on the whole clinical picture (see Supporting Information Appendix S1; Figure 1), Patient 1 (female, P1) and Patient 2 (male, P2) underwent a classic and molecular (Human OmniExpress-12 Bead Chip; Illumina Inc., San Diego, USA) karyotyping on peripheral blood in order to study microdeletion/duplication and UPD involved in Silver–Russell (SRS) and Prader–Willi (PWS) syndromes. This study was approved by an ethics committee and patients gave written informed consent to the investigation, according to the Declaration of Helsinki. No genetic alterations were detected. However, since the clinical presentation of patients includes also cutaneous hypopigmented striae following Blaschko's line along the trunk (P1) and in the limbs (P2; Figure 1c), a SNP array analysis on DNA from skin biopsy was performed in order to investigate a mosaic condition. Unexpectedly, the results showed a diffusely altered pattern of B allele frequencies (BAF) along all the autosomes that was consistent with the coexistence of two different genotypes with an altered ratio between the two haplotypes that could be explained by a chimeric status. Quantification of alleles frequency on skin fibroblasts, demonstrated the presence of two genomes with frequency of 30:70% in P1 (Figure 2a) and of 10:90%, in P2, respectively (Figure 2b). Although SNP array analysis shows a normal log ratio graph, the coexistence of two distinct genomes results in five different tracks (AAAA, AAAB, ABBB, ABAB, BBBB) based on the number of allele combinations in autosomes. Moreover, as shown in Figure 2a, we could observe that the AABB splits into two tracks because of the 30:70% of coexisting genomes. This leads to a patchy BAF scattergram with four-track interchanged with six-track segments (Figure 2a). This arrangement, although present also in P2, is more difficult to identify because of the strong quantitative imbalance of the two coexisting genomes (10:90%).

To better evaluate the percentage of chimerism in P1 and P2, we are taking advantage of a 44-Amplicon Custom Chimerism panel based on Ion AmpliSeq technology as previously reported by Aloisio et al. (2016, identifying 36 SNPs shared with the SNP array chip.

Both NGS data from the blood and the skin DNA samples were collected thus determining the genotypic layout in both tissues. Considering as informative markers only SNPs found in homozygous state (i.e., AA) in the blood sample and in chimeric state (i.e., AG or GG) in the skin sample, it was possible to determine the chimeric allele and the two possible genotypes in the skin. So two distinct...
chimerism values were possible (homozygous or heterozygous state): in P1, 16% or 32% and in P2 3.5% or 7%, respectively (Table 1); however, the NGS analysis cannot discriminate the right value. For these reasons, the comparison between the SNP array and NGS approach suggests that although the quantification of the degree of chimerism
Chimerism found in P1 could be explained by a fertilization of one nucleus by a normal spermatozoa and endoreduplication of the polar body (Figure 3). Conversely, the pathogenetic mechanism behind the P2 is compatible with a tetragametic chimera because the SNP analysis detected five haplotypes that could be explained by two oocytes fertilized by two spermatozoa or fertilization of an ovum and a second polar body by two different spermatozoa (Figure 3). It is really challenging to discriminate these hypotheses because of the high difference between the percentages of the genomes.

In light of chimeric determination in patients, it is possible to make some considerations on the patients' phenotype. Regarding the Silver–Russell-like phenotype in the female patient (P1), it could be explained by the uniparental isodisomy in the endoreduplicated polar body genome (a mechanism first proposed by Yamazawa et al. (2010. Otherwise, the diagnosis of Prader–Willi–like syndrome for patient P2 could not be directly explained by its chimeric status. Since a MS-MLPA in the 15q11 region detects a normal pattern of methylation and no deletion, we suggest in P2 a PWS–like phenotype for which we cannot exclude the chimeric involvement.

In conclusion, many cases of whole-body chimerism are reported in literature; unfortunately most of them present insufficient molecular information allowing to clearly define the mechanism involved in the formation of individual cases. Nonetheless, several cases of proven tetragametic and parthenogenetic chimeras have been described based initially on chromosome heteromorphisms, and more recently on genotyping (Russo et al., 2016; Yamazawa et al, 2010).

Regarding our two patients, the observation of a chimeric state was an unexpected finding that could probably explain the syndromic status at least in P1 while in P2 a genetic
mutation in one of the two coexisting genomes could be the causal event.

To assume chimerism, a priori in the absence of substantial clinical abnormalities is very difficult also because, as demonstrated in our cases, not all the tissues express both genomes, probably leading to an underestimation of this phenomenon. From this perspective, the use of genomewide SNP arrays enables simultaneous evaluation of genomic dosage allowing insights into the mechanisms by which these abnormalities occur. For these reasons, we suggest that the routine use of genotyping SNP arrays analysis for the identification of “hidden” chimerism in patients with few clinical clues.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ORCID

Roberta Bottega1* https://orcid.org/0000-0001-7431-7543
Stefania Cappellani1*
Antonella Fabretto1
Alessandro Mauro Spinelli2
Giovanni Maria Severini1
Michelangelo Aloisio1
Michela Faleschini1
Emmanouil Athanasakis1
Irene Bruno1
Flavio Faletra1
Vanna Pecile1

1Institute for Maternal and Child Health – IRCCS “Burlo Garofolo”, Trieste, Italy
2University of Udine, Udine, Italy

Correspondence

Flavio Faletra, Medical Genetics, Institute for Maternal and Child Health “IRCCS Burlo Garofolo”, Trieste, Italy.
Email: flavio.faletra@burlo.trieste.it

*These authors contributed equally to this work.
REFERENCES

Aloisio, M., Licastro, D., Caenazzo, L., Torboli, V., D’Eustacchio, A., Severini, G. M., & Athanasakis, E. (2016). A technical application of quantitative next generation sequencing for chimerism evaluation. Molecular Medicine Reports, 14(4), 2967–2974. https://doi.org/10.3892/mmr.2016.5593

Biesecker, L. G., & Spinner, N. B. (2013). A genomic view of mosaicism and human disease. Nature Reviews Genetics, 14(5), 307–320. https://doi.org/10.1038/nrg3424

Drexler, C., Glock, B., Vadon, M., Staudacher, E., Dauber, E. M., Ulrich, S., … Wagner, T. (2005). Tetragametic chimerism detected in a healthy woman with mixed-field agglutination reactions in ABO blood grouping. Transfusion, 45(5), 698–703. https://doi.org/10.1111/j.1537-2995.2005.04304.x

Giltay, J. C., Brunt, T., Beemer, F. A., Wit, J. M., van Amstel, H. K., Pearson, P. L., & Wijmenga, C. (1998). Polymorphic detection of a parthenogenetic maternal and double paternal contribution to a 46,XX/46,XY hermaphrodite. The American Journal of Human Genetics, 62(4), 937–940. https://doi.org/10.1086/301796

Green, A. J., Barton, D. E., Jenks, P., Pearson, J., & Yates, J. R. (1994). Chimaerism shown by cytogenetics and DNA polymorphism analysis. Journal of Medical Genetics, 31(10), 816–817. https://doi.org/10.1136/jmg.31.10.816

Kaiser-Rogers, K. A., McFadden, D. E., Livasy, C. A., Dansereau, J., Jiang, R., Knops, J. F., … Robinson, W. P. (2006). Androgenetic/biparental mosaicism causes placental mesenchymal dysplasia. Journal of Medical Genetics, 43(2), 187–192. https://doi.org/10.1136/jmg.2005.033571

Malan, V., Vekemans, M., & Turleau, C. (2006). Chimera and other fertilization errors. Clinical Genetics, 70(5), 363–373. https://doi.org/10.1111/j.1399-0004.2006.00689.x

Ramsay, M., Pfaffenzeller, W., Kotze, E., Bhengu, L., Essop, F., & de Ravel, T. (2009). Chimerism in black southern African patients with true hermaphroditism 46, XX/47XY,+21 and 46,XX/46,XY. Annals of the New York Academy of Sciences, 1151(1), 68–76. https://doi.org/10.1111/j.1749-6632.2008.03570.x

Russo, S., Calzari, L., Mussa, A., Mainini, E., Cassina, M., Di Candia, S., … Larizza, L. (2016). A multi-method approach to the molecular diagnosis of overt and borderline 11p15.5 defects underlying Silver-Russell and Beckwith-Wiedemann syndromes. Clinical Epigenetics, 8(1), 8–23. https://doi.org/10.1186/s13148-016-0183-8

Yamazawa, K., Nakabayashi, K., Kagami, M., Sato, T., Saitoh, S., Horikawa, R., … Ogata, T. (2010). Parthenogenetic chimaerism/mosaicism with a Silver-Russell syndrome-like phenotype. Journal of Medical Genetics, 47(11), 782–785. https://doi.org/10.1136/jmg.2010.079343

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.